Posted by Michael Wonder on 09 Sep 2025
ICER publishes evidence report on treatment for non-cystic fibrosis bronchiectasis
8 September 2025 - There are significant uncertainties regarding long term efficacy of brensocatib; ICER estimates that treatment would achieve common thresholds of cost effectiveness if priced between $3,100 - $3,700/year.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of brensocatib (Brinsupri, Insmed) for the treatment of non-cystic fibrosis bronchiectasis.
